131 |
Behandling med ketamin vid behandlingsresistent depression / Treatment with ketamine in treatment-resistant depressionMariboe, Kim January 2022 (has links)
Inledning: Depression är ett globalt folkhälsoproblem som drabbar människor i alla åldrar oavsett kön. En tredjedel av alla patienter diagnostiserade med depression blir inte hjälpta av dagens behandlingsmetoder och i synnerhet läkemedel. Denna grupp av individer klassificeras som behandlingsresistenta. För individer som lever med behandlingsresistent depression (TRD) är situationen allvarlig. Suicidala tankar (SI) och beteenden är vanligt förekommande och ökar i takt med svårighetsgraden av depressionen. Upptäckten av ketamins snabba effekter mot depression under 2000-talet har givit nytt ljus åt forskningen och mycket forskning görs på området som indikerar på positiva effekter mot TRD och de suicidala benägenheterna. Ketamin är dock ett problematiskt läkemedel med svåra biverkningar som gör situationen mer komplex. Syfte: Syftet med detta litteraturarbete var att undersöka effekterna av intravenöst (iv) ketamin mot TRD och i synnerhet dess antisuicidala effekter. Metod: Fem kliniska studier har analyserats. Två databassökningar gjordes via databasen PubMed med sökorden ”TRD suicidal ideation ketamine infusion treatment” och ” treatment resistant depression ketamine suicidal cognition”. Inkluderade artiklar valdes utifrån fastställda inklusions- och exklusionskriterier. Resultat: Överlag påvisas ett positivt resultat av ketamins antisuicidala effekter vid TRD. Fyra av fem studier visade signifikanta resultat av en singeldos ketamin jämfört med placebo och en studie kunde visa positiva effekter av upprepade infusioner. Medan en studies resultat varken kunde påvisa positiva effekter på kort eller lång sikt. Diskussion: Sammanfattningsvis indikerar resultatet av inkluderade studier på att ketamin i viss grad har positiva effekter på SI vid TRD och att iv ketamin har potential som läkemedel för denna patientgrupp. Dock krävs det mer forskning kring effektens hållbarhet, långtidseffekter, biverkningar och beroenderisken av ketamin. Idag används ketamin i form av det intranasala läkemedlet Spravato mot svår depression, detta med försiktighet på grund av de allvarliga biverkningar som kan följa och dess okända långtidseffekter. / Introduction: Depression is a global public health problem that affects people of all ages regardless of gender. One third of all patients diagnosed with depression are not helped by today's treatment methods. This group of individuals is classified as the treatment resistant. For individuals living with treatment-resistant depression (TRD), the situation is dire. Suicidal thoughts (SI) and behaviors are common and increase with the severity of the depression. The discovery of ketamine's rapid effects against depression in the 21st century has given new light to research and much research are being done in the area that indicates positive effects against TRD and the suicidal tendencies. However, ketamine is a problematic drug with severe side effects that make the situation more complex. Aim: The aim of this review was to investigate the effects of intravenous (iv) ketamine against TRD and in particular its anti-suicidal effects. Method: Five clinical studies have been analyzed. Two database searches were made via the PubMed database with the keywords "TRD suicidal ideation ketamine infusion treatment" and "treatment resistant depression ketamine suicidal cognition". Included articles were selected based on established inclusion and exclusion criteria. Results: Overall, a positive result of ketamine's anti-suicidal effects in TRD is demonstrated. Four out of five studies showed significant results of a single dose of ketamine compared to placebo and one study was able to show positive effects of repeated infusions. While the results of one study could not demonstrate positive effects in the short or long term. Discussion: In summary, the results of included studies indicate that ketamine has, to some extent, positive effects on SI in TRD and that iv ketamine has potential as a drug for this patient group. However, more research is needed concerningdurability of the effect, long-term effects, side effects and the risk of addiction to ketamine. Today, ketamine is used in the form of the intranasal drug Spravato against severe depression, this with caution because of the serious side effects that can follow and its unknown long-term effects.
|
132 |
EVALUATING ANALGESIC INTERVENTIONS FOR ACUTE SURGICAL PAIN, PREVENTION OF PERSISTING POST-SURGICAL PAIN, AND CHRONIC LOW BACK PAIN / Analgesic Interventions in Acute and Chronic PainShanthanna, Harsha January 2019 (has links)
Acute and chronic pain conditions cause significant patient distress, interference with daily activities, and increased health care costs. It is important to evaluate analgesic interventions to improve pain relief, function, quality of life, and also to prevent persisting pain after surgery. This thesis is a combination of studies evaluating analgesic interventions in the setting of acute surgical pain; prevention of persistent post-surgical pain; and chronic low back pain. In part 1, we report our comparison of morphine and hydromorphone in 402 ambulatory surgery patients, for their ability to achieve satisfactory analgesia with minimal emesis using a design of multicentre randomized controlled trial. We observed no differences in their analgesic potential and common side effects and note that appearance of side effects is likely to be idiosyncratic. In part 2, we report our 2×2 factorial feasibility trial to prevent persistent post-surgical pain in patients having elective video-assisted thoracic surgery lobectomies, comparing N-methyl-D-aspartate antagonists versus placebo, and intravenous steroids versus placebo. As our feasibility outcomes were not met, we suggest appropriate considerations for protocol changes before embarking on a definitive larger trial. In part 3, we report on our systematic review and meta-analysis assessing the effectiveness and safety of gabapentinoids (gabapentin and pregabalin) in adult patients with chronic low back pain. We observed that the existing evidence is small and there is minimal improvement in pain and other outcomes with potential for adverse events. We suggest that the use of gabapentinoids for chronic low back pain merits caution and there is need for large high-quality trials. / Thesis / Doctor of Philosophy (PhD) / It is important to evaluate analgesic interventions to decrease pain, improve function, and lessen health care costs. In a randomized controlled trial of day surgery patients, we demonstrate that there are no differences between morphine and hydromorphone in achieving pain relief and common side effects. To prevent persistent post-surgical pain in patients having elective video-assisted thoracic surgery lobectomies, we performed a 2×2 factorial, feasibility randomized controlled trial, to compare N-methyl-D-aspartate antagonists versus placebo, and intravenous steroids versus placebo. We observe that appropriate protocol changes must be made before embarking on a larger trial. Finally, we report our systematic review and meta-analysis on the use of gabapentinoids in adult patients with chronic low back pain and observe that the existing evidence is small and not supportive, and the use of gabapentinoids for chronic low back pain merits caution.
|
133 |
L’effet de l’endotoxémie sur les paramètres pharmacocinétiques et pharmacodynamiques de la kétamine et de la xylazine lors d’anesthésie chez le rat Sprague DawleyVeilleux-Lemieux, Daphnée 01 1900 (has links)
Lorsque l’anesthésie par inhalation ne peut être utilisée chez le rat, la combinaison de kétamine et de xylazine est l’alternative la plus fréquemment utilisée. Les doses administrées peuvent varier selon le protocole expérimental. En présence de fièvre, d’infections ou de processus tumoral accompagné de fièvre, la pharmacocinétique de ces drogues peut être modifiée. Ce projet porte sur l’évaluation des changements physiologiques, hématologiques, biochimiques et pharmacocinétiques chez le rat Sprague Dawley lors d’anesthésie avec le mélange kétamine-xylazine suite à l’administration de trois doses différentes de lipopolysaccharide (LPS).
Après l’administration de LPS, une anesthésie à la kétamine-xylazine fut induite chez des rats Sprague Dawley. Des prélèvements sanguins périodiques ainsi que des mesures des paramètres physiologiques furent effectués afin d’évaluer l’effet du LPS sur la pharmacocinétique des deux drogues ainsi que sur les paramètres biochimiques et hématologiques. Les différentes doses de LPS ont causé certaines modifications notamment en produisant une baisse marquée de la saturation en oxygène et de l’albumine sérique, une augmentation de la durée d’anesthésie ainsi que des lésions hépatiques mineures.
Les paramètres pharmacocinétiques de la kétamine furent peu altérés par l’administration de LPS tandis qu’une diminution de la clairance et une augmentation de l’aire sous la courbe (AUC) furent observées pour la xylazine dans les groupes ayant reçu les doses moyenne et élevée de LPS. Ces résultats montrent que les doses de xylazine doivent être adaptées en présence de LPS pour permettre une anesthésie de courte durée et des changements physiologiques et biochimiques moindres lorsqu’elle est administrée avec de la kétamine. / When inhalation anesthesia cannot be used in laboratory rats, ketamine-xylazine combination is the most frequent alternate regimen. The administrated doses can vary according to the experimental protocol. During fever episodes, infections or tumoral process, the pharmacokinetics of these drugs can be modified. This project focuses on the evaluation of the physiological, hematological, biochemical and pharmacokinetics changes in Sprague Dawley rats during ketamine-xylazine anesthesia, after administration of three different doses of lipopolysaccharide (LPS).
After administration of LPS to Sprague Dawley rats, ketamine-xylazine anesthesia was induced. Periodic blood samplings and monitoring of physiologic parameters were made in order to evaluate the effect of LPS on ketamine-xylazine pharmacokinetics and hematological and biochemical parameters. The different LPS doses caused specific parameter modifications including a marked decrease of oxygen blood saturation and serum albumin, a longer anesthesia duration and minor hepatic lesions.
No significant modifications of pharmacokinetics parameters of ketamine were observed. An increase of area under curve (AUC) and a decrease of xylazine clearance were noted in groups who received medium and large doses of LPS. These results show that that xylazine doses need to be adapted in the presence of LPS, to allow a shorter duration anaesthesia and lesser physiological and biochemical changes when administered with ketamine.
|
134 |
Les effets du vieillissement sur la pharmacodynamie et la pharmacocinétique de la kétamine et de la xylazine chez le rat Sprague-DawleyGiroux, Marie-Chantal 09 1900 (has links)
Chez les animaux de laboratoire, même si les anesthésiques par inhalation sont généralement plus sécuritaires que les injectables, leur utilité est souvent restreinte lorsqu’un protocole expérimental exige une autre approche. Des combinaisons d’anesthésiques contenant de la kétamine sont considérées comme l’option de choix pour les anesthésies injectables chez les rats. Le vieillissement entraîne des changements dégénératifs au niveau de la structure et la fonction des organes, modifiant souvent à la pharmacocinétique des drogues. Ce projet porte sur l’évaluation des changements pharmacodynamiques (physiologiques, biochimiques et histologiques) et pharmacocinétiques, lors d’une combinaison anesthésique de kétamine-‐xylazine chez le rat Sprague-‐Dawley vieillissant. Une anesthésie à la kétamine-‐xylazine fut induite chez des rats Sprague-‐Dawley de différents âges. Afin d’évaluer l’effet du vieillissement sur le métabolisme des deux drogues, des prélèvements sanguins périodiques pour l’analyse de la
pharmacocinétique ainsi que des mesures des paramètres physiologiques, biochimiques et une histopathologie furent effectués. Le vieillissement a causé certaines modifications notamment en produisant une diminution de la saturation d’oxygène, une baisse marquée de la fréquence cardiaque et respiratoire, une hypoalbuminémie ainsi qu’une augmentation de la durée d’anesthésie. Les paramètres pharmacocinétiques de la kétamine et de la xylazine furent grandement affectés par le vieillissement causant une augmentation progressive significative de l’aire sous la courbe (AUC) et du temps de demi-‐vie, ainsi qu’une diminution de la clairance. À la lumière de ces résultats, les doses de kétamine et de xylazine doivent être adaptées chez les rats vieillissants pour permettre une anesthésie de durée raisonnable et un réveil sans complications. / In laboratory animals, even if inhalation anesthetics are generally safer than injecting, their usefulness is often restrained when an experimental design does not allow it. For this reason, ketamine combinations are considered the option of choice for injecting anesthesia in rats. Aging brings degenerative changes in the structure and function of the organs, often affecting the pharmacokinetics of drugs. This project focuses on the evaluation of physiological, pharmacokinetic, biochemical and histological changes during a ketamine-‐xylazine anesthetic combination in aging Sprague-‐Dawley rats. Anesthesia with ketamine-‐xylazine was induced in Sprague-‐Dawley rats of different ages. To assess the effect of aging on the metabolism of both drugs, periodic blood samples for pharmacokinetic analysis and measurements of physiological, biochemical and histological parameters were performed. Aging have made some changes for example a decrease in oxygen saturation, a sharp drop in heart and respiratory rate, hypoalbuminemia and an increase in the duration of anesthesia. The pharmacokinetic parameters of ketamine and xylazine were greatly affected in older animals, causing a significant increase in the area Under the curve (AUC) and the half-‐life time, and a decrease in clearance. In the light of these results, dosage of ketamine and xylazine must be adapted in aging rats to allow a short anesthesia and an awakening
without complications.
|
135 |
Potencial evocado auditivo de tronco encefálico em gerbils submetidos à isquemia e sepse / Auditory brainstem response in gerbils submitted to ischemia and sepsisLima, Janaina Patrício de 23 May 2012 (has links)
Introdução: O Acidente Vascular Cerebral do tipo isquêmico é um quadro clínico que afeta milhares de pessoas no mundo. Como resultado dessa injúria observamos morte neuronal, e no decorrer natural de recuperação, o indivíduo pode desenvolver a sepse. A sepse é uma resposta inflamatória sistêmica que pode levar o indivíduo a morte. No seu desenvolvimento há a produção de diversas citocinas que caracterizam o processo inflamatório no organismo. Para avaliar as condições clínicas de um paciente com esse quadro o Potencial Evocado Auditivo de Tronco Encefálico (PEATE) pode ser útil,uma vez que ele não é um procedimento invasivo, sua técnica é rápida e pode ser feita à beira do leito. Porém, por outro lado, o PEATE pode ser sensível ao uso de alguns anestésicos. Objetivos: Fazer análise das citocinas IL-6, IL-10 e TNF- no decorrer da sepse; verificar os valores de latência do PEATE em gerbils submetidos à isquemia e sepse; e verificar a influência do anestésico ketamina associado à xilazina nos valores do PEATE desses animais. Método: Foram coletados os PEATEs de 72 gerbils machos adultos que foram divididos em 6 grupos, a saber: controle, sepse, isquemia, sham, isquemia com sepse e sham com sepse. Para a indução de sepse foi aplicado Lipopolissacarídeo (LPS) intraperitoneal nos gerbils. Os animais foram anestesiados antes das coletas com ketamina associada à xilazina, seus PEATEs foram coletados antes de qualquer procedimento (coleta base), após isquemia e 2, 4, 8 e 24 horas após a aplicação de LPS. Foi avaliada a latência absoluta da onda V, e os valores foram comparados intra e intergrupos. As citocinas IL-6, IL-10 e TNF- foram analisadas e comparadas em cada grupo estudado. Resultados: Foi observado aumento das citocinas IL-6, IL-10 e TNF- no decorrer da sepse. Houve diferença estatisticamente significante nos grupos submetidos à sepse no valor da latência da onda V em relação aos demais grupos. Observou-se, também, aumento da latência da onda V após a aplicação sucessiva do anestésico ketamina/xilazina em todos os grupos estudados. Conclusão: Houve aumento dos níveis das citocinas IL-6, IL-10 e TNF- nos animais que sofreram aplicação de LPS, revelando uma alteração de expressão gênica de moléculas pró (IL-6 e TNF-) e anti-inflamatória (IL-10) no decorrer da sepse.O PEATE se mostrou sensível a sepse com aumento de latência da onda V no desenvolver da doença no modelo experimental utilizado. O uso de Ketamina associada à xilazina influenciou o resultado do PEATE, aumentando o valor de latência absoluta da onda V do PEATE / Introduction: The Cerebrovascular Accident of ischemic type is a clinical condition affecting thousands of people around the world. As a result of this injury we observe neuronal death, and along the natural course of recovery individuals may develop sepsis. Sepsis is a systemic inflammatory response that may lead to death. Along its development, several cytokines are produced that characterize the inflammatory process on the body. To assess the clinical conditions of a patient with this condition the Auditory Brainstem Response (ABR) may be useful, as it is not an invasive procedure, it is fast to perform, and may be done at the patients bedside. On the other hand, the ABR may be sensitive to the use of some anesthetics. Objectives: To perform an analysis of the IL-6, IL-10 and TNF- cytokines in the course of sepsis; to verify the ABR latency values in gerbils submitted to ischemia and sepsis; and to verify the influence of the ketamine/xylazine anesthetic on the ABR values in these animals. Method: ABRs were collected for 72 adult male gerbils divided into 6 groups, namely: control, sepsis, ischemia, sham, ischemia with sepsis and sham with sepsis. For induction of sepsis, intraperitoneal lipopolysaccharide (LPS) was injected into the gerbils. The animals were anesthetized prior to the collections with ketamine/xylazine, theirs ABRs were collected before any procedure (base collection), after ischemia and 2, 4, 8 and 24 hours after the LPS injection. The absolute latency of the V wave was assessed, and values were compared within and among groups. The IL-6, IL-10 and TNF- cytokines were analyzed and compared in each study group. Results: An increase was observed in IL-6, IL-10 and TNF- cytokines in the course of sepsis. There was a statistically significant difference in the groups submitted to sepsis in the value of the V wave latency compared to the other groups. An increase in the V wave latency was also observed after successive injection of the ketamine/xylazine anesthetic in all study groups. Conclusion: There was an increase in the levels of IL-6, IL-10 and TNF- cytokines in the animals injected with LPS, revealing a change of the gene expression of the pro- (IL-6 and TNF-) and anti-inflammatory (IL-10) molecules in the course of sepsis. The ABR proved to be sensitive to sepsis with an increase of the V wave latency in the course of the disease on the experimental model used. The use of ketamine/xylazine influenced the results of the ABR, increasing the absolute latency value for the V wave of the ABR
|
136 |
Efeitos comportamentais do canabidiol em um modelo de psicose induzida por S(+)-ketamina em ratos Wistar / Behavioral effects of cannabidiol in a model of S (+) - ketamine induced psychosis in Wistar ratsRoss, Jana Batista de 23 May 2012 (has links)
A esquizofrenia é uma desordem neuropsiquiátrica de importância significativa para as pesquisas na área da saúde, porém, apesar de ser alvo de inúmeros estudos clínicos e básicos ainda são levantadas muitas dúvidas a respeito de sua etiologia, fisiopatologia e tratamento. Nos últimos anos, hipóteses que relacionam a esquizofrenia a alterações em sistemas neurotransmissores têm sido bem relevantes. Atualmente a hipótese glutamatérgica complementa a dopaminérgica, já que o bloqueio de receptores glutamatérgicos do tipo NMDA induz sintomas do tipo psicóticos em indivíduos saudáveis e exacerba ou precipita sintomas da esquizofrenia em indivíduos portadores da doença, sugerindo que um estado hipofuncional desses receptores possa causar alterações secundárias em outros sistemas neurotransmissores e provocar tanto os sintomas positivos e negativos quanto os déficits cognitivos da doença. O canabidiol (CBD) é um composto derivado da Cannabis sativa que não apresenta os efeitos psicotomiméticos e os sintomas colaterais geralmente provocados pela utilização da planta e que são, em sua maioria, atribuídos ao delta-9-tetrahidrocanabinol (THC). Recentemente os estudos a respeito da participação do sistema endocanabinóide em diversos estados fisiológicos e, também em transtornos psiquiátricos, apontam o uso terapêutico de canabinóides como uma estratégia promissora para o controle e prevenção de alguns sintomas ligados a transtornos psicóticos. O perfil antipsicótico do CBD já foi comprovado em modelos experimentais e até em análises clínicas, indicando que esse composto é capaz de prevenir estados psicóticos transitórios, provocados tanto pelo THC quanto pela ketamina, em modelos de psicose induzida. O objetivo deste trabalho foi incrementar as informações já existentes sobre o perfil antipsicótico proposto para o CBD, porém, em três tipos de tarefas comportamentais em roedores, que representam três classes de sintomas do tipo psicóticos que se assemelham aos sintomas da esquizofrenia: atividade locomotora, inibição pré-pulso do reflexo de sobressalto (PPI) e teste de interação social. No modelo utilizado, a S(+)-ketamina (KET) é eficaz na indução de comportamentos que representem sintomas do tipo psicóticos - provocou hiperlocomoção, déficit no filtro sensório-motor e prejuízo no comportamento social. Esses são foram reduzidos quando realizado pré-tratamento com clozapina, com exceção do teste de interação social. Os efeitos do CBD são de acordo com o que é descrito na literatura, apresentando uma curva em U farmacológica característica e diferentes efeitos 6 de acordo com a dose empregada. A análise no monitor de atividades indica que o pré- tratamento com CBD na dose de 30 mg/kg previne a hiperlocomoção induzida por KET, contrastando com o pré-tratamento com CBD na dose de 60 mg/kg, que provoca o aumento do comportamento exploratório após a administração de KET. No PPI, o CBD na dose de 30 mg/kg previne o déficit provocado pela administração de KET, demonstrando-se eficaz para o tratamento de prejuízos cognitivos que acompanham as psicoses; e aumenta o reflexo de sobressalto quando associado a KET. Porém, no teste de interação social, não foram detectadas diferenças significativas. Portanto, com esses resultados, demonstrou-se que o CBD pode ser realmente efetivo para o tratamento de determinados sintomas dos transtornos psicóticos, assim como indicado em alguns trabalhos já desenvolvidos. / Schizophrenia is a psychiatric disorder of significant importance for research in health care, however, despite being the target of numerous clinical and basic studies, there are still many doubts raised about its etiology, pathophysiology and treatment. In recent years, schizophrenia hypotheses that relate to changes in neurotransmitter systems have been very relevant. Currently, the glutamatergic hypothesis complements the dopaminergic, since blockade of NMDA glutamate receptors induces psychotic symptoms in healthy individuals and exacerbate them in patients with schizophrenia, suggesting that a hipofuncional state of these receptors may cause secondary changes in other neurotransmitter systems, leading to positive and negative symptoms and also to cognitive deficits of the disease. Cannabidiol (CBD) is a compound derived from Cannabis sativa that does not show neither the psychotomimetic effects nor side effect symptoms typically caused by the plant use, which are mostly attributed to delta-9-tetrahydrocannabinol (THC). Recently studies about the involvement of the endocannabinoid system in various physiological states and also in psychiatric disorders, suggest the therapeutic use of cannabinoids as a promising strategy for the prevention and control of some symptoms linked, for example, to anxiety, epilepsy and psychotic disorders. The antipsychotic profile of CBD has been confirmed in experimental 7 models and even in clinical trials, indicating that this compound is capable of preventing transient psychotic states caused both by THC and S (+)-ketamine (KET) in psychosis-induced models. The objective of this study was to enhance the existing information on the antipsychotic profile proposed for the CBD, however, three types of behavioral tasks were made for the analysis of three classes of psychotic-like symptoms in rodents, which are manifested through hyperlocomotion (positive symptoms), impairment in social interaction (negative symptoms) and a deficit in sensorimotor gating (cognitive deficits). The effects achieved with CBD are in accordance with the described in literature, a characteristic Ushaped curve and different pharmacological effects according to dose used. The analysis in the open field reveals that animals pretreated with CBD at a dose of 30 mg/kg shows a reduction in KET-induced hyperlocomotion, contrasting with the effects of CBD at a dose of 60 mg/kg, that enhances exploratory behavior after KET injection. In the PPI, the CBD at a dose of 30 mg/kg prevented the deficit caused by KET administration, showing effectiveness for the treatment of cognitive impairments that accompany psychosis; and enhances startle reflex when associated to KET. Therefore, with these results, it was demonstrated that CBD may be really effective for the treatment of certain symptoms of psychotic disorders, in accordance to some already developed studies.
|
137 |
Har ketamin effekt mot terapiresistent depression?Arildsson, Mathilda January 2019 (has links)
Depression är ett syndrom som drabbar mer än 300 miljoner människor i världen. Tillståndet förekommer i individuella variationer men vanliga symtom är nedstämdhet, energiförlust, störningar av sömn och aptit samt känslor av skuld och skam. En svår depression kan innebära lidande och stor funktionsförlust för den drabbade. Idag används både psykologisk och farmakologisk behandling, men det finns en problematik kring att det kan dröja veckor eller månader innan klinisk effekt ses av antidepressiva läkemedel. Därutöver blir en tredjedel av patienterna inte tillräckligt hjälpta av den behandling som finns att tillgå. Detta brukar kallas terapiresistent depression (TRD) och är för närvarande svårbehandat. Ketamin är ett narkotikaklassat läkemedel som används för induktion och underhåll av anestesi men som även förekommer som missbruksdrog. Fynd har visat att engångstillförsel av ketamin eventuellt kan ge en snabb antidepressiv effekt hos patienter med TRD. Ketamin är för närvarande inte godkänt för indikationen depression i Sverige. Syftet med denna litteraturstudie var att utvärdera om ketamin har effekt mot TRD. Fem randomiserade kontrollerade studier som hämtats ur databasen PubMed användes. I tre studier undersöktes intravenös tillförsel av ketamin varav en gav upprepade doser, en studie undersökte intravenöst esketamin i varierande doser och en studie undersökte effekten av intranasalt ketamin. Sammantaget visar resultatet att ketamin har effekt mot terapiresistent depression. Efter 24 timmar kunde statistiskt signifikanta skillnader avseende depressionens svårighetsgrad observeras hos de som fått ketamin jämfört med placebo (p <0,05). Ketamin gav 7–16 poängs större reduktion av depressiva symtom än placebo enligt använd skattningsskala, vilket motsvarade en genomsnittlig förändring från svår/medelsvår depression till mild depression. Resultatet visade även statistiskt signifikanta skillnader avseende behandlingsrespons (minst 50 % reduktion av symtompoäng på använd skattningsskala) efter 24 timmar (p <0,05). Andelen patienter med respons varierade mellan 44–71 % jämfört med 0–6 % för placebo och 28 % för aktiv placebo (midazolam). Även om resultatet från aktuella studier verkar lovande för ketamin som antidepressiv behandling krävs ytterligare studier på långtidseffekter och säkerhet vid upprepad tillförsel i en större studiepopulation. / Depression is a syndrome characterized by depressed mood, loss of interest and energy, feelings of guilt or worthlessness and thoughts of death and suicide. Over 300 million people suffer from depression and it is one of the leading causes of disability in the world. Today’s treatment for depression includes psychological treatment as well as pharmacological treatment. While there are many antidepressant drugs, it can take up to weeks or even months before a clinical effect in the severity of the depression can be noticed. In addition, one third of the patients do not achieve remission. These patients, after treatment with two antidepressant medications given at adequate doses for an adequate duration, are considered to have treatment-resistant depression (TRD). Ketamine is a drug long used for its anesthetic and analgesic effects, but it is also known as a party-drug that can cause out-of-body experience. However, it has also been found that a single-dose ketamine may give people with TRD a rapid antidepressant effect, within 24 hours. In contrast to current antidepressant medications which primarily acts on the monoaminergic system, ketamine instead acts on the glutamatergic system. The aim of this study was to evaluate if ketamine has an effect on people suffering from TRD. This study is a literature review where five randomized controlled trials on the effect of ketamine in patients with TRD have been analyzed. Four studies evaluated the effect of intravenous ketamine where one of them used a varied dose frequency and one of them used esketamine in various doses. The fifth study evaluated the effect of intranasal administration of ketamine. All studies were found in the database PubMed. The overall result shows that ketamine has an effect on TRD. After 24 hours all the studies showed a significant improvement in the severity of the depression with ketamine treatment compared to placebo (p <0.05). Ketamine treatment resulted in a 7-16 points larger reduction in depressive symptoms on the scales used compared to placebo. This represents on average a change from severe/moderately severe depression to mild depression. There was also a significant difference in response (at least 50 % reduction in points from baseline on the scale used) after 24 hours with ketamine treatment compared to placebo (p <0.05). The proportion of ketamine treated patients with response varied between 44-71 % compared to 0-6 % for placebo and 28 % for active placebo (midazolam). Even though ketamine seems to have an effect on patients with TRD there is still limited knowledge of how the antidepressant effect shall be maintained and the safety of long-term use. Further studies are needed to determine if ketamine will be an option in future antidepressant treatment against TRD.
|
138 |
Zebrafish como organismo-modelo para análises de efeitos comportamentais e toxicológicas da cetamina empregando cromatografia em fase gasosa e estatística multivariada / Zebrafish as an organism-model for analysis of behavioral effects and toxicological analysis of ketamine employing gas chromatography and multivariate statisticsCampos, Eduardo Geraldo de 11 March 2016 (has links)
A cetamina é uma droga amplamente utilizada e o seu uso inadequado tem sido associado à graves consequências para a saúde humana. Embora as propriedades farmacológicas deste agente em doses terapêuticas sejam bem conhecidas, existem poucos estudos sobre os efeitos secundários induzidos por doses não-terapêuticas, incluindo os efeitos nos estados de ansiedade e agressividade. Neste contexto, os modelos animais são uma etapa importante na investigação e elucidação do mecanismo de ação a nível comportamental. O zebrafish (Danio rerio) é um novo organismo-modelo, interessante e promissor, uma vez que apresenta alta similaridade fisiológica, genética e neuroquímica com seres humanos, respostas comportamentais bem definidas e rápida absorção de compostos de interesse em meio aquoso além de apresentar uma série de vantagens em relação aos modelos mamíferos tais como manutenção de baixo custo, prática e executável em espaços reduzidos. Nesse sentido, faz-se necessário a execução de ensaios comportamentais em conjunto com análises estatísticas robustas e rápidas tais como ANOVA e Métodos Multivariados; e também o desenvolvimento de métodos analíticos sensíveis, precisos e rápidos para determinação de compostos de interesse em matrizes biológicas provenientes do animal. Os objetivos do presente trabalho foram a investigação dos efeitos da cetamina sobre a ansiedade e a agressividade em zebrafish adulto empregando Testes de Claro-Escuro e Testes do Espelho e métodos estatísticos univariados (ANOVA) e multivariados (PCA, HCA e SIMCA) assim como o desenvolvimento de método analítico para determinação da cetamina em matriz biológica proveniente do animal, empregando Extração Líquido-Líquido e Cromatografia em Fase Gasosa acoplada ao Detector de Nitrogênio-Fósforo (GC-NPD). Os resultados comportamentais indicaram que a cetamina produziu um efeito significativo dose-dependente em zebrafish adulto na latência à área clara, no número de cruzamentos entre as áreas e no tempo de exploração da área clara. Os resultados das análises SIMCA e PCA mostraram uma maior similaridade entre o grupo controle e os grupos de tratamento expostos às doses mais baixas (5 e 20 mg L-1) e entre os grupos expostos às doses de 40 e 60 mg L-1. Na análise por PCA, dois componentes principais responderam por 88,74% de toda a informação do sistema, sendo que 62,59% da informação cumulativa do sistema foi descrito pela primeira componente principal. As classificações HCA e SIMCA seguiram uma evolução lógica na distribuição das amostras por classes. As doses mais altas de cetamina induziram uma distribuição mais homogênea das amostras enquanto as doses mais baixas e o controle resultaram em distribuições mais dispersas. No Teste do Espelho, a cetamina não induziu efeitos significativos no comportamento dos animais. Estes resultados sugerem que a cetamina é modulador de comportamentos ansiosos, sem efeitos indutores de agressividade. Os resultados da validação do método cromatográfico indicaram uma extração com valores de recuperação entre 33,65% e 70,89%. A curva de calibração foi linear com valor de R2 superior a 0,99. O limite de detecção (LOD) foi de 1 ng e o limite de quantificação (LOQ) foi de 5 ng. A exatidão do método cromatográfico manteve-se entre - 24,83% e - 1,258%, a precisão intra-ensaio entre 2,67 e 14,5% e a precisão inter-ensaio entre 1,93 e 13,9%. / Ketamine is a widely used drug and its inappropriate use has been associated with serious consequences for human health. Although the pharmacological properties of this agent in therapeutic doses are well known, there are few studies about the side effects induced at non-therapeutic doses, including the effects on states of anxiety and aggression. In this context, animal models are an important step in the investigation and elucidation of the mechanism of action at the behavioral level. The zebrafish (Danio rerio) is a new organism model, interesting and promising, since it presents high physiological, genetics and neurochemistry similarity in relation to humans, well-defined behavioral responses and rapid absorption of interesting compounds in an aqueous medium, apart from presents several advantages over mammalian models such as practical, low cost maintenance and executable in reduced spaces. In this sense, it is necessary to perform behavioral tests in conjunction with robust and rapid statistical analysis such as ANOVA and multivariate methods; and also the development of sensitive, accurate and rapid analytical methods to determination of compounds of interest in biological matrices from the animal. The objectives of this study were to investigate the effects of ketamine on anxiety and aggression in adult zebrafish using Light-Dark and Mirror Biting tests and univariate (ANOVA) and multivariate (PCA, HCA and SIMCA) statistical methods and to develop an analytical method for determination of ketamine in biological animal matrices using Liquid-Liquid Extraction and Gas Chromatography coupled with Nitrogen-Phosphorus Detector (GC-NPD). The behavioral results of Light-Dark Test indicated that ketamine produced a significant dose-dependent response in the latency to light area, in the number of midline crossings and in the time spent in light area. Results of SIMCA and PCA analysis showed a greater similarity between the control group and treatment groups exposed to lower doses (5 and 20 mg L-1) and between the treatment groups at doses of 40 and 60 mg L-1. In the analysis PCA, two principal components accounted for 88,74% of all the system information and 62,59% of the cumulative information of the system were described for the first principal component. The HCA and SIMCA results showed a logical evolution in the distribution of samples per class. The higher dose of ketamine induced a more homogeneous distribution of the samples while the lower doses and control resulted in more dispersed distribution. In the Mirror Test, ketamine induced no significant effect on the behavior of animals. These results suggest that ketamine is a modulator of anxious behavior without inducing aggressive effects. The results of the validation of chromatographic method indicated an extraction with recovery ranged between 33,65% to 70,89%. Calibration curve was linear with R2 value higher than 0,99. The limit of detection (LOD) was 1 ng and the limit of quantification (LOQ) was 5 ng. The accuracy of gas chromatographic method ranged between - 24,83% and - 1,258%, intra-assay precision between 2,67 and 14,5% and inter-assay precision between 1,93 and 13,9%.
|
139 |
Etude de l'impact des antagonistes du récepteur N-méthyl-D-aspartate (NMDA) dans la douleur neuropathique / Study of the impact of N-methyl-D-aspartate (NMDA) receptor antagonists on neuropathic painMartin, Elodie 10 November 2017 (has links)
Les antagonistes du récepteur N-méthyl-D-aspartate (NMDA) comme la kétamine, le dextrométhorphane et la mémantine sont utilisés pour la prise en charge de la douleur neuropathique. La kétamine est très efficace contre les douleurs neuropathiques réfractaires aux traitements conventionnels. Cependant, son utilisation est limitée du fait de nombreux effets indésirables. Un relais antalgique est alors proposé. Ce travail de thèse s’insère dans un programme de recherche dédié aux antagonistes du récepteur NMDA dans la prise en charge de la douleur neuropathique. Le premier objectif était d’évaluer dans une étude clinique randomisée, en simple insu, en groupes parallèles, contrôlée versus placebo, les effets antalgiques du dextrométhorphane et de la mémantine, administrés en relais de la kétamine chez 60 patients souffrant de douleurs neuropathiques d’origine périphérique. L’impact de ces traitements sur le statut cognitivo-émotionnel des patients et leur qualité de vie a également été examiné, ainsi que la modulation des effets de ces médicaments par le polymorphisme génétique impliqué dans le métabolisme (CYP2D6, CYP3A4,5), la biodisponibilité et l’élimination (NR1I2) de ces deux molécules. En parallèle une étude mécanistique centrée sur le dextrométhorphane a été réalisée chez vingt volontaires sains (étude randomisée, en double aveugle, en groupes croisés). L’objectif était d’étudier dans un modèle d’hyperalgie induite par le froid « Freeze injury » les caractéristiques pharmacologiques et mécanistiques déterminant les effets anti-nociceptifs, centraux et cognitifs du dextrométhorphane ainsi que le polymorphisme génétique impliqué dans leur modulation. Chez les patients, les effets antalgiques immédiats de la kétamine ont été confirmés et s’accompagnaient de l’amélioration des scores d’anxiété et de dépression, des aspects cognitifs et affectifs et du sommeil. Toutefois, par rapport au placebo, la mémantine et le dextrométhorphane n’ont pas permis de renforcer significativement l’antalgie induite par la kétamine. Chez les volontaires sains, le dextrométhorphane a révélé des effets anti-hyperalgiques suite à une sensibilisation périphérique et centrale. Cependant, aucun effet analgésique sur la douleur thermique aiguë n’a été observé. Ces deux approches clinique et mécanistique concernant l’effet curatif des antagonistes du récepteur NMDA ont permis d’une part de montrer : 1 - chez le patient, l’effet curatif prolongé de la kétamine et l’intérêt du dextrométhorphane et de la mémantine dans la prise en charge du retentissement négatif de la douleur neuropathique sur le statut cognitivo-émotionnel et la qualité de vie des patients; 2 - chez le volontaire sain, l’efficacité anti-hyperalgique du dextrométhorphane sur les phénomènes de sensibilisation périphérique et centrale ainsi que ses répercussions sédatives et cognitives. En complément de ces deux études et dans le but de confirmer en clinique les effets curatifs du dextrométhorphane sur le triptyque douleur-cognition-émotion, une étude clinique randomisée, en double aveugle, en groupes parallèles, contrôlée versus placebo est en cours de réalisation chez 40 patientes souffrant de douleur neuropathique chimio-induite subséquente au traitement du cancer du sein. En conclusion de ce travail de thèse, l’étude des effets du dextrométhorphane dans deux populations différentes souligne l’intérêt de la recherche translationnelle. Chez le sujet volontaire sain, le dextrométhorphane exerce un effet anti-hyperalgique marqué et provoque des effets centraux délétères. Chez le patient présentant une douleur neuropathique d’origine périphérique et étant répondeur à la kétamine, seule une tendance est observée en faveur de l’effet anti-nociceptif du dextrométhorphane donné en relais de la kétamine. En revanche l’administration de dextrométhorphane s’accompagne d’un certain bénéfice au niveau cognitif et sur la qualité de vie des patients. / N-methyl-D-aspartate (NMDA) receptor antagonists such as ketamine, dextromethorphan and memantine have gained an increasing interest in the management of neuropathic pain. In Pain Clinics, ketamine is widely used in the relief of neuropathic pain. However, its use in clinical practice is limited due to its numerous side effects. It is therefore necessary to propose to patients a drug relay with other NMDA receptor antagonists. This work is part of an academic program research dedicated to NMDA receptor antagonists in the management of neuropathic pain. Its first objective was to evaluate the antalgic effects of dextromethorphan and memantine. This randomized, single-blind, parallel-group, placebo-controlled study in 60 ketamine responder patients aimed also to assess the cognitive-emotional status of patients and their quality life. In parallel, a mechanistic study focusing on dextromethorphan was performed in 20 healthy volunteers in a randomized, double-blind, cross-over, placebo-controlled study. The objective was to investigate in a freeze-injury model the pharmacokinetic and mechanistic characteristics of the anti-nociceptive, central and cognitive effects of dextromethorphan as well as the genetic polymorphism involved in its response variability.In patients, the immediate analgesic effects of ketamine were confirmed with improved anxiety and depression scores, cognitive and affective aspects of pain, and different sleep parameters. However, memantine and dextromethorphan, compared to placebo, did not significantly increase the ketamine-induced analgesia. The analysis of the genetic polymorphism did not reveal any variability in the analgesic efficacy of these treatments. In healthy volunteers, dextromethorphan revealed anti-hyperalgesic effects following peripheral and central sensitization but no analgesic effect on acute heat pain. Moreover, the variability of the anti-nociceptive activity of dextromethorphan described in the literature seems to be more related to the genetic polymorphism of the CYP2D6 gene than to that of the CYP3A4,5 and ABCB1 genes. Finally, dextrorphan, the main active metabolite of dextromethorphan, appears to be responsible for the deleterious sedative and cognitive effects of the drug. These two clinical and mechanistic approaches concerning the curative effect of the NMDA receptor antagonists showed : 1 - in patients, the prolonged curative effect of ketamine and the interest of dextromethorphan and memantine in the management of the neuropathic pain-related cognitive-emotional and quality of life impairment; 2 - in healthy volunteers, the anti-hyperalgesic efficacy of dextromethorphan on peripheral and central sensitization and its sedative and cognitive side effects. In addition to these two studies, a randomized, double-blind, parallel-group, placebo-controlled clinical study is ongoing in 40 patients with chemotherapy-induced peripheral neuropathic pain subsequently to the treatment of breast cancer. In conclusion the assessment of the effects of dextromethorphan in two different populations led to discordant results. In the healthy volunteer, dextromethorphan exerts a marked anti-hyperalgesic effect and causes deleterious central effects. In the patient with peripheral neuropathic pain, only a trend is observed in favor of the anti-nociceptive effect of dextromethorphan given in ketamine responder patients. More studies with larger population are needed to determine the importance of the CYP2D6, CYP3A4,5 and ABCB1 genetic polymorphisms on the anti-nociceptive activity of dextromethorphan. The translational approach of this thesis does not allow a firm conclusion on the clinical use of dextromethorphan in the curative treatment of chronic peripheral neuropathic pain. The use of dextromethorphan as a preventive agent via other administration routes (i.e. local) or in combination with other drugs, all require further exploration in order to improve the benefit/risk ratio of this molecule.
|
140 |
L’effet de l’endotoxémie sur les paramètres pharmacocinétiques et pharmacodynamiques de la kétamine et de la xylazine lors d’anesthésie chez le rat Sprague DawleyVeilleux-Lemieux, Daphnée 01 1900 (has links)
Lorsque l’anesthésie par inhalation ne peut être utilisée chez le rat, la combinaison de kétamine et de xylazine est l’alternative la plus fréquemment utilisée. Les doses administrées peuvent varier selon le protocole expérimental. En présence de fièvre, d’infections ou de processus tumoral accompagné de fièvre, la pharmacocinétique de ces drogues peut être modifiée. Ce projet porte sur l’évaluation des changements physiologiques, hématologiques, biochimiques et pharmacocinétiques chez le rat Sprague Dawley lors d’anesthésie avec le mélange kétamine-xylazine suite à l’administration de trois doses différentes de lipopolysaccharide (LPS).
Après l’administration de LPS, une anesthésie à la kétamine-xylazine fut induite chez des rats Sprague Dawley. Des prélèvements sanguins périodiques ainsi que des mesures des paramètres physiologiques furent effectués afin d’évaluer l’effet du LPS sur la pharmacocinétique des deux drogues ainsi que sur les paramètres biochimiques et hématologiques. Les différentes doses de LPS ont causé certaines modifications notamment en produisant une baisse marquée de la saturation en oxygène et de l’albumine sérique, une augmentation de la durée d’anesthésie ainsi que des lésions hépatiques mineures.
Les paramètres pharmacocinétiques de la kétamine furent peu altérés par l’administration de LPS tandis qu’une diminution de la clairance et une augmentation de l’aire sous la courbe (AUC) furent observées pour la xylazine dans les groupes ayant reçu les doses moyenne et élevée de LPS. Ces résultats montrent que les doses de xylazine doivent être adaptées en présence de LPS pour permettre une anesthésie de courte durée et des changements physiologiques et biochimiques moindres lorsqu’elle est administrée avec de la kétamine. / When inhalation anesthesia cannot be used in laboratory rats, ketamine-xylazine combination is the most frequent alternate regimen. The administrated doses can vary according to the experimental protocol. During fever episodes, infections or tumoral process, the pharmacokinetics of these drugs can be modified. This project focuses on the evaluation of the physiological, hematological, biochemical and pharmacokinetics changes in Sprague Dawley rats during ketamine-xylazine anesthesia, after administration of three different doses of lipopolysaccharide (LPS).
After administration of LPS to Sprague Dawley rats, ketamine-xylazine anesthesia was induced. Periodic blood samplings and monitoring of physiologic parameters were made in order to evaluate the effect of LPS on ketamine-xylazine pharmacokinetics and hematological and biochemical parameters. The different LPS doses caused specific parameter modifications including a marked decrease of oxygen blood saturation and serum albumin, a longer anesthesia duration and minor hepatic lesions.
No significant modifications of pharmacokinetics parameters of ketamine were observed. An increase of area under curve (AUC) and a decrease of xylazine clearance were noted in groups who received medium and large doses of LPS. These results show that that xylazine doses need to be adapted in the presence of LPS, to allow a shorter duration anaesthesia and lesser physiological and biochemical changes when administered with ketamine.
|
Page generated in 0.293 seconds